05-Jul-2012 - European Medicines Agency (EMA)

Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)

The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).

On 2 September 2011, Janssen-Cilag International NV submitted an application to extend the marketing authorisation for Velcade in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin lymphoma. At the time of the withdrawal the application was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).

Velcade was first authorised in the European Union on 26 April 2004 and is indicated in combination with melphalan and prednisone to treat patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with a bone marrow transplant. Velcade is also indicated as monotherapy to treat progressive multiple myeloma in patients who have received at least one prior therapy and have already had or are unsuitable for a bone marrow transplant.
In its official letter, the company stated that it decided to withdraw the application after the CHMP indicated that the data provided do not support a positive benefit-risk balance.

Velcade continues to be authorised in the currently approved indications.

Facts, background information, dossiers
  • European Medicines Agency
  • Velcade
  • Janssen-Cilag
More about European Medicines Agency
  • News

    EMA to relocate to Amsterdam

    The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken today by the EU 27 Member States in the margins of the General Affairs Council (Art.50). The Agency now has just over 16 months to prepare for the move and take up its operations in Am ... more

    EMA prepares for Brexit

    The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s (UK’s) withdrawal from the European Union (EU) and the Agency’s relocation. “Preparing for the move, managing the ... more

    EMA’s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

    Merck and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of avelumab (BAVENCIO®) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC), a rar ... more

More about Janssen-Cilag
  • News

    Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

    Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial ... more

    Janssen Affiliate Cilag GmbH International Acquires Covagen AG

    Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology p ... more

    Discontinuation of sale of ceftobiprole in Switzerland

    Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authoriza ... more

  • Companies

    Janssen-Cilag N.V.

    Janssen-Cilag develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world. We view ourselves as a full-service partner for all stakeholders in healthcare, as evidenced in the first line ... more

    Janssen-Cilag GmbH

    Our mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented. We believe that challenging something is the best way to change it. So every day, in more than 150 countries, we bring cutting-edge science and the most creative m ... more

    Janssen-Cilag S.A.